摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-苯二酰亚氨基-2-丁炔 | 113439-83-1

中文名称
1-苯二酰亚氨基-2-丁炔
中文别名
N-(2-丁炔基)邻苯二甲酰亚胺;1-邻苯二甲酰亚氨基-2-丁炔
英文名称
2-(but-2-yn-1-yl)isoindoline-1,3-dione
英文别名
N-(2-butynyl)phthalimide;2-but-2-ynylisoindole-1,3-dione
1-苯二酰亚氨基-2-丁炔化学式
CAS
113439-83-1
化学式
C12H9NO2
mdl
——
分子量
199.209
InChiKey
COPWPECHFWIYSP-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    217-218 °C
  • 沸点:
    334.5±25.0 °C(Predicted)
  • 密度:
    1.273±0.06 g/cm3(Predicted)
  • 稳定性/保质期:

    遵照规定使用和储存,则不会分解。

计算性质

  • 辛醇/水分配系数(LogP):
    1.9
  • 重原子数:
    15
  • 可旋转键数:
    1
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.17
  • 拓扑面积:
    37.4
  • 氢给体数:
    0
  • 氢受体数:
    2

安全信息

  • 危险品标志:
    Xn,Xi
  • 安全说明:
    S37/39
  • 危险类别码:
    R36/37/38
  • 海关编码:
    2925190090
  • WGK Germany:
    2
  • 储存条件:
    存放于2-8°C阴凉干燥处

SDS

SDS:882475faff143d2b3028afe287c9557c
查看

Section 1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE
Product identifiers
Product name : N-(2-Butynyl)phthalimide
CAS-No. : 113439-83-1
Relevant identified uses of the substance or mixture and uses advised against
Identified uses : Laboratory chemicals, Manufacture of substances



Section 2. HAZARDS IDENTIFICATION
Classification of the substance or mixture
Classification according to Regulation (EC) No 1272/2008 [EU-GHS/CLP]
Acute toxicity, Oral (Category 4)
Skin irritation (Category 2)
Eye irritation (Category 2)
Specific target organ toxicity - single exposure (Category 3)
Classification according to EU Directives 67/548/EEC or 1999/45/EC
Harmful if swallowed. Irritating to eyes, respiratory system and skin.
Label elements
Labelling according Regulation (EC) No 1272/2008 [CLP]
Pictogram
Signal word Warning
Hazard statement(s)
H302 Harmful if swallowed.
H315 Causes skin irritation.
H319 Causes serious eye irritation.
H335 May cause respiratory irritation.
Precautionary statement(s)
P261 Avoid breathing dust/ fume/ gas/ mist/ vapours/ spray.
P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove
contact lenses, if present and easy to do. Continue rinsing.
Supplemental Hazard none
Statements
According to European Directive 67/548/EEC as amended.
Hazard symbol(s)
R-phrase(s)
R22 Harmful if swallowed.
R36/37/38 Irritating to eyes, respiratory system and skin.
S-phrase(s)
S26 In case of contact with eyes, rinse immediately with plenty of water and
seek medical advice.
Other hazards - none

Section 3. COMPOSITION/INFORMATION ON INGREDIENTS
Substances
Synonyms : 1-Phthalimido-2-butyne
Formula : C12H9NO2
Molecular Weight : 199,21 g/mol
Component Concentration
N-(2-Butynyl)phthalimide
CAS-No. 113439-83-1 -

Section 4. FIRST AID MEASURES
Description of first aid measures
General advice
Consult a physician. Show this safety data sheet to the doctor in attendance.
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.
In case of skin contact
Wash off with soap and plenty of water. Consult a physician.
In case of eye contact
Rinse thoroughly with plenty of water for at least 15 minutes and consult a physician.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician.
Most important symptoms and effects, both acute and delayed
To the best of our knowledge, the chemical, physical, and toxicological properties have not been
thoroughly investigated.
Indication of any immediate medical attention and special treatment needed
no data available

Section 5. FIREFIGHTING MEASURES
Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special hazards arising from the substance or mixture
Carbon oxides, nitrogen oxides (NOx)
Advice for firefighters
Wear self contained breathing apparatus for fire fighting if necessary.
Further information
no data available

Section 6. ACCIDENTAL RELEASE MEASURES
Personal precautions, protective equipment and emergency procedures
Use personal protective equipment. Avoid dust formation. Avoid breathing vapors, mist or gas. Ensure
adequate ventilation. Evacuate personnel to safe areas. Avoid breathing dust.
Environmental precautions
Do not let product enter drains.
Methods and materials for containment and cleaning up
Pick up and arrange disposal without creating dust. Sweep up and shovel. Keep in suitable, closed
containers for disposal.
Reference to other sections
For disposal see section 13.

Section 7. HANDLING AND STORAGE
Precautions for safe handling
Avoid contact with skin and eyes. Avoid formation of dust and aerosols.
Provide appropriate exhaust ventilation at places where dust is formed.Normal measures for preventive fire
protection.
Conditions for safe storage, including any incompatibilities
Store in cool place. Keep container tightly closed in a dry and well-ventilated place.
Specific end uses
no data available

Section 8. EXPOSURE CONTROLS/PERSONAL PROTECTION
Control parameters
Components with workplace control parameters
Exposure controls
Appropriate engineering controls
Handle in accordance with good industrial hygiene and safety practice. Wash hands before breaks and
at the end of workday.
Personal protective equipment
Eye/face protection
Safety glasses with side-shields conforming to EN166 Use equipment for eye protection tested
and approved under appropriate government standards such as NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique
(without touching glove's outer surface) to avoid skin contact with this product. Dispose of
contaminated gloves after use in accordance with applicable laws and good laboratory practices.
Wash and dry hands.
The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and
the standard EN 374 derived from it.
Body Protection
Complete suit protecting against chemicals, The type of protective equipment must be selected
according to the concentration and amount of the dangerous substance at the specific workplace.
Respiratory protection
For nuisance exposures use type P95 (US) or type P1 (EU EN 143) particle respirator.For higher
level protection use type OV/AG/P99 (US) or type ABEK-P2 (EU EN 143) respirator cartridges.
Use respirators and components tested and approved under appropriate government standards
such as NIOSH (US) or CEN (EU).

Section 9. PHYSICAL AND CHEMICAL PROPERTIES
Information on basic physical and chemical properties
a) Appearance Form: solid
b) Odour no data available
c) Odour Threshold no data available
d) pH no data available
e) Melting point/freezing Melting point/range: 219 - 223 °C
point
f) Initial boiling point and no data available
boiling range
g) Flash point no data available
h) Evaporation rate no data available
i) Flammability (solid, gas) no data available
j) Upper/lower no data available
flammability or
explosive limits
k) Vapour pressure no data available
l) Vapour density no data available
m) Relative density no data available
n) Water solubility no data available
o) Partition coefficient: n- log Pow: 2,433
octanol/water
p) Autoignition no data available
temperature
q) Decomposition no data available
temperature
r) Viscosity no data available
s) Explosive properties no data available
t) Oxidizing properties no data available
Other safety information
no data available

Section 10. STABILITY AND REACTIVITY
Reactivity
no data available
Chemical stability
no data available
Possibility of hazardous reactions
no data available
Conditions to avoid
no data available
Incompatible materials
Oxidizing agents
Hazardous decomposition products
Other decomposition products - no data available

Section 11. TOXICOLOGICAL INFORMATION
Information on toxicological effects
Acute toxicity
no data available
Skin corrosion/irritation
no data available
Serious eye damage/eye irritation
no data available
Respiratory or skin sensitization
no data available
Germ cell mutagenicity
no data available
Carcinogenicity
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity
no data available
Specific target organ toxicity - single exposure
Inhalation - May cause respiratory irritation.
Specific target organ toxicity - repeated exposure
no data available
Aspiration hazard
no data available
Potential health effects
Inhalation May be harmful if inhaled. Causes respiratory tract irritation.
Ingestion Harmful if swallowed.
Skin May be harmful if absorbed through skin. Causes skin irritation.
Eyes Causes serious eye irritation.
Signs and Symptoms of Exposure
To the best of our knowledge, the chemical, physical, and toxicological properties have not been
thoroughly investigated.
Additional Information
RTECS: Not available

Section 12. ECOLOGICAL INFORMATION
Toxicity
no data available
Persistence and degradability
no data available
Bioaccumulative potential
no data available
Mobility in soil
no data available
Results of PBT and vPvB assessment
no data available
Other adverse effects
no data available

Section 13. DISPOSAL CONSIDERATIONS
Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company. Contact a licensed
professional waste disposal service to dispose of this material. Dissolve or mix the material with a
combustible solvent and burn in a chemical incinerator equipped with an afterburner and scrubber.
Contaminated packaging
Dispose of as unused product.

Section 14. TRANSPORT INFORMATION
UN number
ADR/RID: - IMDG: - IATA: -
UN proper shipping name
ADR/RID: Not dangerous goods
IMDG: Not dangerous goods
IATA: Not dangerous goods
Transport hazard class(es)
ADR/RID: - IMDG: - IATA: -
Packaging group
ADR/RID: - IMDG: - IATA: -
Environmental hazards
ADR/RID: no IMDG Marine pollutant: no IATA: no
Special precautions for user
no data available

Section 15. REGULATORY INFORMATION
This safety datasheet complies with the requirements of Regulation (EC) No. 1907/2006.
Safety, health and environmental regulations/legislation specific for the substance or mixture
no data available
Chemical Safety Assessment
no data available

Section 16. OTHER INFORMATION
Further information
Copyright 2012 Co. LLC. License granted to make unlimited paper copies for internal use
only.
The above information is believed to be correct but does not purport to be all inclusive and shall be
used only as a guide. The information in this document is based on the present state of our knowledge
and is applicable to the product with regard to appropriate safety precautions. It does not represent any
guarantee of the properties of the product. Corporation and its Affiliates shall not be held
liable for any damage resulting from handling or from contact with the above product. See
and/or the reverse side of invoice or packing slip for additional terms and conditions of sale.

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    1-苯二酰亚氨基-2-丁炔乙醇1,3-双(2,6-二-异丙基苯基)咪唑-2-亚基金(I)氯化物 、 Selectfluor 作用下, 以 为溶剂, 反应 18.0h, 以76%的产率得到2-(2-fluoro-3-oxobutyl)isoindoline-1,3-dione
    参考文献:
    名称:
    使用 Selectfluor 对邻苯二甲酰亚胺保护的炔丙胺进行金催化的区域选择性氧氟化/氧二氟化与二酮化
    摘要:
    α-氟、β-邻苯二甲酰亚胺酮、α,α-二氟、β-邻苯二甲酰亚胺酮或 β-邻苯二甲酰亚胺 α-二酮的选择性形成通过金催化的氧氟化/氧二氟化或双氧化反应进行了描述。还进行了喹喔啉核的同时组装和邻苯二甲酰亚胺保护基团的去除。
    DOI:
    10.1002/ejoc.202101524
  • 作为产物:
    描述:
    1-(三甲基硅基)丙炔(1,3-二氧代异吲哚啉-2-基)甲基乙酯 在 iron(III) chloride 作用下, 以 1,2-二氯乙烷 为溶剂, 反应 1.5h, 以93%的产率得到1-苯二酰亚氨基-2-丁炔
    参考文献:
    名称:
    自动串联催化:通过 N-Acyliminium 离子化学通过分子间铁催化的酰胺炔基化/水合级联反应获得功能化酮的廉价和绿色途径
    摘要:
    自串联催化:铁 (III) 催化剂被证明可有效催化各种烷氧基、乙酰氧基内酰胺和羟基内酰胺的分子间炔化反应。这种化学反应通过突出铁盐σ-刘易斯酸度的新方面来拓宽铁催化的范围。更重要的是,这种方法适用于前所未有的串联分子间炔基化/分子内水合序列,可以方便地获得新的羰基结构。
    DOI:
    10.1002/chem.202102357
点击查看最新优质反应信息

文献信息

  • AMINE DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS
    申请人:Acucela, Inc.
    公开号:US20160193181A1
    公开(公告)日:2016-07-07
    Provided are amine derivative compounds, pharmaceutical compositions thereof, and methods of treating ophthalmic diseases and disorders, such as age-related macular degeneration and Stargardt's Disease, using said compounds and compositions.
    提供的是胺衍生物化合物、其药物组合物,以及使用所述化合物和组合物治疗眼科疾病和障碍的方法,例如年龄相关的黄斑变性和斯达格特病。
  • Palladium-catalysed carboformylation of alkynes using acid chlorides as a dual carbon monoxide and carbon source
    作者:Yong Ho Lee、Elliott H. Denton、Bill Morandi
    DOI:10.1038/s41557-020-00621-x
    日期:2021.2
    Hydroformylation, a reaction that installs both a C–H bond and an aldehyde group across an unsaturated substrate, is one of the most important catalytic reactions in both industry and academia. Given the synthetic importance of creating new C–C bonds, the development of carboformylation reactions, wherein a new C–C bond is formed instead of a C–H bond, would bear enormous synthetic potential to rapidly
    加氢甲酰化是一种在不饱和底物上同时安装 C-H 键和醛基的反应,是工业界和学术界最重要的催化反应之一。鉴于创造新的 C-C 键的合成重要性,发展碳甲酰化反应,其中形成新的 C-C 键而不是 C-H 键,将具有巨大的合成潜力,可以在有价值的合成中迅速增加分子的复杂性醛类。然而,利用外源 CO 源的四组分反应固有的苛刻复杂性使得直接碳甲酰化反应的发展成为一项艰巨的挑战。在这里,我们描述了一种催化策略,该策略使用现成的芳酰作为碳亲电试剂和 CO 源,与空间拥挤的氢硅烷串联,进行炔烃的立体选择性碳甲酰化。将该协议扩展到四种化学发散性羰基化,进一步突出了该策略在羰基化化学中提供的创造性机会。
  • Modular Cyclopentenone Synthesis through the Catalytic Molecular Shuffling of Unsaturated Acid Chlorides and Alkynes
    作者:Yong Ho Lee、Elliott H. Denton、Bill Morandi
    DOI:10.1021/jacs.0c10832
    日期:2020.12.16
    general strategy for the intermolecular synthesis of polysubstituted cyclopentenones using palladium catalysis. Overall, this reaction is achieved via a molecular shuffling process involving an alkyne, an α,β-unsaturated acid chloride, which serves as both the alkene and carbon monoxide source, and a hydrosilane to create three new C-C bonds. This new carbon monoxide-free pathway delivers the products
    我们描述了使用催化分子间合成多取代环戊烯酮的一般策略。总体而言,该反应是通过涉及炔烃、α,β-不饱和酰(作为烯烃和一氧化碳来源)和氢硅烷的分子改组过程实现的,以产生三个新的 CC 键。这种新的无一氧化碳途径提供了具有优异产量的产品。此外,区域选择性是对环戊烯酮合成常规方法的补充。此外,还提出了一组区域和化学发散反应,以强调这种新策略的合成潜力。
  • [EN] 8 - SULFO - IMIDAZOTETRAZIN- 4 - ONE COMPOUNDS AND THEIR USE AS ANTICANCER DRUG<br/>[FR] COMPOSÉS 8-SULFO-IMIDAZOTÉTRAZIN-4-ONE ET LEUR UTILISATION EN TANT QUE MÉDICAMENT ANTICANCÉREUX
    申请人:PHARMINOX LTD
    公开号:WO2012085501A1
    公开(公告)日:2012-06-28
    Compounds of formula (I) and pharmaceutically acceptable salts, hydrates or solvates thereof are provided (I) wherein B, X, and Y are as defined herein. The compounds are of use in methods of regulating cell proliferation, inhibiting cell cycle progression, and/or promoting apoptosis, and in the treatment of proliferative disorders.
    提供具有化学式(I)及其药用可接受的盐、合物或溶剂化合物(I)的其中B、X和Y的定义如本文所述。这些化合物在调节细胞增殖、抑制细胞周期进展和/或促进凋亡的方法中有用,并用于治疗增生性疾病。
  • Deoxygenative C–C Bond-Forming Processes via a Net Four-Electron Reductive Coupling
    作者:David P. Todd、Benjamin B. Thompson、Alex J. Nett、John Montgomery
    DOI:10.1021/jacs.5b08448
    日期:2015.10.14
    The nickel-catalyzed coupling of enones or enals with alkynes in the presence of silane and titanium alkoxide reductants provides direct access to skipped diene products. The process involves a net four-electron reductive coupling and proceeds with deoxygenation of the starting enone or enal. A new class of well-defined nickel(0) precatalysts bearing an unhindered N-heterocyclic carbene ligand, which
    硅烷醇盐还原剂的存在下,烯酮或烯醛与炔烃催化偶联可直接获得跳过的二烯产物。该过程涉及净四电子还原耦合,并进行起始烯酮或烯醛的脱氧。一类新的明确定义的 (0) 预催化剂带有不受阻碍的 N-杂环卡宾配体,是在优化过程中开发的,对于转化效率至关重要。该策略允许将 α,β-不饱和羰基底物的高反应性用于偶联,同时挤出氧原子,从而实现烯烃安装的无痕策略。
查看更多

同类化合物

(1Z,3Z)-1,3-双[[((4S)-4,5-二氢-4-苯基-2-恶唑基]亚甲基]-2,3-二氢-5,6-二甲基-1H-异吲哚 鲁拉西酮杂质33 鲁拉西酮杂质07 马吲哚 颜料黄110 顺式-六氢异吲哚盐酸盐 顺式-2-[(1,3-二氢-1,3-二氧代-2H-异吲哚-2-基)甲基]-N-乙基-1-苯基环丙烷甲酰胺 顺式-2,3,3a,4,7,7a-六氢-1H-异吲哚 顺-N-(4-氯丁烯基)邻苯二甲酰亚胺 降莰烷-2,3-二甲酰亚胺 降冰片烯-2,3-二羧基亚胺基对硝基苄基碳酸酯 降冰片烯-2,3-二羧基亚胺基叔丁基碳酸酯 阿胍诺定 阿普斯特降解杂质 阿普斯特杂质FA 阿普斯特杂质68 阿普斯特杂质29 阿普斯特杂质27 阿普斯特杂质26 阿普斯特杂质19 阿普斯特杂质08 阿普斯特杂质03 阿普斯特杂质 阿普斯特二聚体杂质 阿普斯特 防焦剂MTP 铝酞菁 铁(II)1,2,3,4,8,9,10,11,15,16,17,18,22,23,24,25-十六氟-29H,31H-酞菁 铁(II)2,9,16,23-四氨基酞菁 钠S-(2-{[2-(1,3-二氧代-1,3-二氢-2H-异吲哚-2-基)乙基]氨基}乙基)氢硫代磷酸酯 酞酰亚胺-15N钾盐 酞菁锡 酞菁二氯化硅 酞菁 单氯化镓(III) 盐 酞美普林 邻苯二甲酸亚胺 邻苯二甲酰基氨氯地平 邻苯二甲酰亚胺,N-((吗啉)甲基) 邻苯二甲酰亚胺阴离子 邻苯二甲酰亚胺钾盐 邻苯二甲酰亚胺钠盐 邻苯二甲酰亚胺观盐 邻苯二亚胺甲基磷酸二乙酯 那伏莫德 过氧化氢,2,5-二氢-5-苯基-3H-咪唑并[2,1-a]异吲哚-5-基 达格吡酮 诺非卡尼 螺[环丙烷-1,1'-异二氢吲哚]-3'-酮 螺[异吲哚啉-1,4'-哌啶]-3-酮盐酸盐 葡聚糖凝胶G-25